<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449813</url>
  </required_header>
  <id_info>
    <org_study_id>BY1023/NL511</org_study_id>
    <nct_id>NCT00449813</nct_id>
  </id_info>
  <brief_title>The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)</brief_title>
  <official_title>The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare two different endpoint measures: heartburn as assessed by
      the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by
      the patient using the ReQuest™ questionnaire. The assessment is made in GERD-patients treated
      with a daily dose of 40 mg oral pantoprazole over an 8-week period.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion-rate does not seem feasible anymore to obtain te required number of patients before
    the end of the trial.
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of misclassification on day 14 based on heartburn as assessed by the investigator compared to symptom assessment by the patient using the ReQuest™-gastrointestinal (GI) questionnaire</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of misclassification on day 14 based on acid regurgitation as assessed by the investigator compared to symptom assessment by the patient using the ReQuest™-GI questionnaire</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Non-erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg Pantoprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg Pantoprazole</description>
    <arm_group_label>1.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Outpatients of at least 18 years of age

          -  History of GERD-related symptoms of at least 6 months prior to baseline visit

          -  Endoscopically-confirmed GERD or non-erosive GERD

        Exclusion Criteria:

          -  Zollinger-Ellison syndrome or other gastric hypersecretory condition

          -  Acute peptic ulcer and/or ulcer complications

          -  Pyloric stenosis

          -  Severe or unstable cardiovascular, pulmonary, and/or endocrine disease

          -  Pregnancy, breast feeding, intention to become pregnant during the course of the study
             or lack of reliable contraception in women of child-bearing potential

          -  Intake of any medication for the purpose of eradication of Helicobacter pylori (H.
             pylori) within the last 28 days prior to study start

          -  Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs including
             cyclooxygenase-2 (COX-2) inhibitors for more than 3 consecutive days within the last
             28 days prior to study start; with the exception of acetylsalicylic acid not more than
             150 mg per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Oudkerk Pool, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala Klieniken, Zwolle, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>BT Oss</city>
        <zip>5342</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Den Helder</city>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>EH Geldrop</city>
        <zip>5664</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Basel</city>
        <zip>4001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Basel</city>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Biel/Bienne</city>
        <zip>2502</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Bülach</city>
        <zip>8180</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Locarno, TI.</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Luzern</city>
        <zip>6003</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Luzern</city>
        <zip>6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Reinach BL</city>
        <zip>4153</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Sion</city>
        <zip>1950</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Winterthur</city>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Zürich</city>
        <zip>8050</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>Nycomed</name_title>
    <organization>Nycomed</organization>
  </responsible_party>
  <keyword>Gastroesophageal reflux disease (GERD)</keyword>
  <keyword>Non erosive reflux disease (NERD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

